Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan-Dec:36:1533317521996147.
doi: 10.1177/1533317521996147.

Therapeutic Potential of Neu1 in Alzheimer's Disease Via the Immune System

Aiza Khan  1 , Sumit Das  2   3 , Consolato Sergi  1   4
Affiliations
Review

Therapeutic Potential of Neu1 in Alzheimer's Disease Via the Immune System

Aiza Khan et al. Am J Alzheimers Dis Other Demen. 2021 Jan-Dec.

Abstract

Alzheimer's Disease (AD) is pathologically characterized by the accumulation of soluble oligomers causing extracellular beta-amyloid deposits in form of neuritic plaques and tau-containing intraneuronal neurofibrillary tangles in brain. One proposed mechanism explaining the formation of these proteins is impaired phagocytosis by microglia/macrophages resulting in defective clearance of soluble oligomers of beta-amyloid stimulating aggregation of amyloid plaques subsequently causing AD. However, research indicates that activating macrophages in M2 state may reduce toxic oligomers. NEU1 mutation is associated with a rare disease, sialidosis. NEU1 deficiency may also cause AD-like amyloidogenic process. Amyloid plaques have successfully been reduced using NEU1.Thus, NEU1 is suggested to have therapeutic potential for AD, with lysosomal exocytosis being suggested as underlying mechanism. Studies however demonstrate that NEU1 may activate macrophages in M2 state, which as noted earlier, is crucial to reducing toxic oligomers. In this review, authors discuss the potential therapeutic role of NEU1 in AD via immune system.

Keywords: Alzheimer’s; Neu1; immune system; neuroinflammation; pathophysiology.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Association between Neu1 and Alzheime1.
Figure 2.
Figure 2.
Therapeutic potential of Neu1 in Alzheimer’s disease via the immune system.
See this image and copyright information in PMC

References

    1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspect Med. 2011;1(1):a006189. - PMC - PubMed
    1. Chaudhary A, Maurya PK, Yadav BS, Singh S, Mani A. Current therapeutic targets for Alzheimer’s disease. J Biomed. 2018;3:74–84.
    1. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Ann Rev Neurosci. 1994;17(1):489–517. - PubMed
    1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356. - PubMed
    1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimers disease at 25 years. EMBO Mol Med. 2016;8:595–608. - PMC - PubMed

LinkOut - more resources